Abiraterone Acetate

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 3690 publications

Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01.

Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01.

Journal: Future oncology (London, England)

Published: April 14, 2026

Proliferation associates with greater sensitivity to androgen receptor pathway inhibition for metastatic prostate cancer.

Proliferation associates with greater sensitivity to androgen receptor pathway inhibition for metastatic prostate cancer.

Journal: The Journal of clinical investigation

Published: March 31, 2026

First Real-World Data of Olaparib Combination Treatment with Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC): Descriptive Analysis of 154 Patients Enrolled in the Early Access Program in France.

First Real-World Data of Olaparib Combination Treatment with Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC): Descriptive Analysis of 154 Patients Enrolled in the Early Access Program in France.

Journal: Drugs - real world outcomes

Published: March 26, 2026

Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer.

Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer.

Journal: Journal for immunotherapy of cancer

Published: March 13, 2026

LC-MS/MS Method for Therapeutic Drug Monitoring of Abiraterone, Darolutamide, Apalutamide, Enzalutamide, and Metabolites in Prostate Cancer Patients.

LC-MS/MS Method for Therapeutic Drug Monitoring of Abiraterone, Darolutamide, Apalutamide, Enzalutamide, and Metabolites in Prostate Cancer Patients.

Journal: International journal of molecular sciences

Published: March 04, 2026

Registry-based randomised phase II study of Enzalutamide versus Abiraterone: assessing cognitive function in eLderly patients with metastatic castration-resistant Prostate cancer (REAL-Pro).

Registry-based randomised phase II study of Enzalutamide versus Abiraterone: assessing cognitive function in eLderly patients with metastatic castration-resistant Prostate cancer (REAL-Pro).

Journal: ESMO real world data and digital oncology

Published: February 27, 2026

Temporal trends in diagnostic work-up, treatment, and mortality in locally advanced prostate cancer in 2016-2024: nationwide, population-based study in Sweden.

Temporal trends in diagnostic work-up, treatment, and mortality in locally advanced prostate cancer in 2016-2024: nationwide, population-based study in Sweden.

Journal: Acta oncologica (Stockholm, Sweden)

Published: February 19, 2026

Treatment of metastatic hormone-sensitive prostate cancer

Treatment of metastatic hormone-sensitive prostate cancer

Journal: Urologie (Heidelberg, Germany)

Published: February 13, 2026

Unanticipated Testicular Involvement in Prostate Carcinoma: A Case Report.

Unanticipated Testicular Involvement in Prostate Carcinoma: A Case Report.

Journal: Cureus

Published: February 10, 2026

Serendipity, steroids and science.

Serendipity, steroids and science.

Journal: The Journal of steroid biochemistry and molecular biology

Published: February 04, 2026

Excellent Response to Combined 223Ra-dichloride and Enzalutamide After Failure of 177Lu-PSMA Radioligand Therapy.

Excellent Response to Combined 223Ra-dichloride and Enzalutamide After Failure of 177Lu-PSMA Radioligand Therapy.

Journal: Clinical nuclear medicine

Published: January 24, 2026

Distinct Expression Patterns and Clinical Associations of the IRX Gene Family Across Hormone-Sensitive Cancers.

Distinct Expression Patterns and Clinical Associations of the IRX Gene Family Across Hormone-Sensitive Cancers.

Journal: Cancers

Published: January 22, 2026

Showing 1-12 of 3,690

Last Updated: 04/28/2026